Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.46 |
| ▸ | HTR6 | P50406 | 9/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14953556 | 0.87 | ACLY (0.46) | ACLYHTR6CA2TSHRKMT2A | |
| SCHEMBL14953494 | 0.82 | ACLY (0.43) | ACLYHTR6CA2TSHRKMT2A | |
| SCHEMBL3563939 | 0.81 | ACLY (0.62) | ACLYCA2KMT2ACA12CA9 | |
| SCHEMBL3563271 | 0.77 | CA12 (0.56) | HTR6CA2TSHRKMT2ACA12 | |
| SCHEMBL5029975 | 0.76 | CCR2 (0.44) | ACLYCA2TSHRCA12CA9 | |
| SCHEMBL14732435 | 0.75 | FABP3 (0.58) | HTR6CA2CA1CA4CA6 | |
| SCHEMBL6829699 | 0.75 | HTR6 (0.60) | HTR6CHRM1 | |
| SCHEMBL28414053 | 0.74 | NOD1 (0.61) | HTR6CA2CA1KMT2AHSD17B10 | |
| SCHEMBL8999447 | 0.74 | RAPGEF4 (0.39) | ACLYCA2TSHRKMT2ACA12 | |
| SCHEMBL27598460 | 0.74 | ACLY (0.41) | ACLYTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | disclosed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
| CN-1720227-A | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD (IN) | 2006-01-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | ACLY 4542/4885HTR6 56/4885CA2 3663/4885 |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | ACLY 4542/4885HTR6 56/4885CA2 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.